Active	Status	Sponsor type	Region	Phase	Filter
11 Active 0 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mehta, Priyesh
NCT04967664 / 2021-001409-64: Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery	Active, not recruiting	3	409	Europe, US	Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system	Averitas Pharma, Inc., Averitas Pharma, Inc.	Post Surgical Neuropathic Pain	01/25	08/25
MODEL, NCT05516992: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine	Active, not recruiting	3	417	US	SB-01 For Injection, Sham Needle	Spine BioPharma, Inc, MCRA	Lumbar Degenerative Disc Disease	02/25	08/25
MSB-DR004, NCT06325566: Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain	Recruiting	3	300	US	Rexlemestrocel-L + HA mixture, Saline	Mesoblast, Ltd.	Degenerative Disc Disease	10/26	10/27
OA05, NCT05620563: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain	Completed	2	147	US	LY3857210, Placebo	Eli Lilly and Company	Osteoarthritis	06/23	06/23
NCT05630196: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain	Completed	2	138	US	LY3857210, Placebo	Eli Lilly and Company	Chronic Low-back Pain	06/23	06/23
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection	Completed	2	63	US	TNX-102 SL, Placebo SL Tablet	Tonix Pharmaceuticals, Inc.	Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID	07/23	07/23
NCT05620576: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).	Completed	2	131	US	LY3857210, Placebo	Eli Lilly and Company	Diabetic Peripheral Neuropathic Pain	07/23	08/23
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain	Recruiting	2	384	US	RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo	Reata, a wholly owned subsidiary of Biogen	Diabetic Peripheral Neuropathic Pain	08/26	08/26
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain	Recruiting	2	10000	US	LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo	Eli Lilly and Company	Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain	04/27	04/27
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode	Active, not recruiting	N/A	44467	US		Guardant Health, Inc., Premier Research Group plc	Colorectal Cancer	03/24	12/25